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Choline kinase inhibition induces exacerbated
endoplasmic reticulum stress and triggers apoptosis
via CHOP in cancer cells
E Sanchez-Lopez1, T Zimmerman2, T Gomez del Pulgar3, MP Moyer4, JC Lacal Sanjuan*,3 and A Cebrian3
Endoplasmic reticulum (ER) is a central organelle in eukaryotic cells that regulates protein synthesis and maturation.
Perturbation of ER functions leads to ER stress, which has been previously associated with a broad variety of diseases.
ER stress is generally regarded as compensatory, but prolonged ER stress has been involved in apoptosis induced by several
cytotoxic agents. Choline kinase a (ChoKa), the first enzyme in the Kennedy pathway, is responsible for the generation of
phosphorylcholine (PCho) that ultimately renders phosphatidylcholine. ChoKa overexpression and high PCho levels have been
detected in several cancer types. Inhibition of ChoKa has demonstrated antiproliferative and antitumor properties; however,
the mechanisms underlying these activities remain poorly understood. Here, we demonstrate that ChoKa inhibitors (ChoKIs),
MN58b and RSM932A, induce cell death in cancer cells (T47D, MCF7, MDA-MB231, SW620 and H460), through the prolonged
activation of ER stress response. Evidence of ChoKIs-induced ER stress includes enhanced production of glucose-regulated
protein, 78 kDa (GRP78), protein disulfide isomerase, IRE1a, CHOP, CCAAT/enhancer-binding protein beta (C/EBPb) and TRB3.
Although partial reduction of ChoKa levels by small interfering RNA was not sufficient to increase the production of ER stress
proteins, silencing of ChoKa levels also show a decrease in CHOP overproduction induced by ChoKIs, which suggests that ER
stress induction is due to a change in ChoKa protein folding after binding to ChoKIs. Silencing of CHOP expression leads to a
reduction in C/EBPb, ATF3 and GRP78 protein levels and abrogates apoptosis in tumor cells after treatment with ChoKIs,
suggesting that CHOP maintains ER stress responses and triggers the pro-apoptotic signal. Consistent with the differential
effect of ChoKIs in cancer and primary cells previously described, ChoKIs only promoted a transient and moderated
ER stress response in the non-tumorogenic cells MCF10A. In conclusion, pharmacological inhibition of ChoKa induces cancer
cell death through a mechanism that involves the activation of exaggerated and persistent ER stress supported by CHOP
overproduction.
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Phosphatidylcholine (PC) is a major structural component in
eukaryotic membranes and a reservoir of the lipid second
messengers diacylglycerol and phosphatidic acid.1 Choline
kinase alpha (ChoKa) is the first enzyme of PC biosynthesis.
Transformation of cells with the Ras oncogene (found in about
30% of all human tumors) increases both ChoKa activity and
intracellular levels of phosphorylcholine (PCho),2–5 as also
reported in several human tumors including lung, breast,
colon, ovary and prostate.6–10 ChoKa is a critical requirement
for breast tumor progression11,12 and its overexpression is
considered as prognostic factor in lung cancer,13 and is
associated with increased mortality in hepatocellular carci-
noma.14 Specific ChoKa inhibitors (ChoKIs) or small interfer-
ing RNA (siRNA) inhibition have been proposed as a novel
broad-spectrum antitumor strategy with proven antiprolifera-
tive activity against oncogene-transformed cells and human
cancer cells.15–24 MN58b (1,4-[4-40-Bis-{[4-(dimethylamine)
pyridinium-1-yl] methyl} diphenyl] butane dibromide) has
demonstrated potent antiproliferative and antitumoral activity
in vivo.12,16,20–23,25 MN58b has been used as a lead molecule
for a first generation of compounds, synthesized to improve
the tolerability of ChoKIs in vivo. RSM932A (also named TCD-
717)26 has been selected among several molecules as it
provided the best results in vitro and in vivo and is in the
Phase I clinical trial for the treatment of solid tumors (http://
clinicaltrials.gov/ct2/show/NCT01215864).
We have previously demonstrated that MN58b shows
specific cytotoxic effects mediated by an increase of
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ceramides in hematopoietic cancer cell lines, whereas
primary cells suffer a reversible arrest in G1 being able to
recover and proliferate once the drug is removed.23–25
However, the precise mechanism by which this selective
effect is achieved is not fully understood.
Endoplasmic reticulum (ER) is a central organelle engaged
in lipid synthesis, protein folding and maturation. Cellular
perturbations, including hypoxia, failure of protein synthesis,
folding, transport or degradation, Ca2þ overload and PC
depletion can disturb theER function resulting inER stress.27–32
ER stress-induced apoptosis is becoming increasingly
recognized as an important pathogenic factor in a vast
number of diseases, including neurodegenerative diseases,
diabetes, atherosclerosis and renal disease, and has been
recently associated with the mechanism of action of antitumor
agents such as vorinostat, sorafenib and bortezomib.33–38
ER disturbance triggers several specific signaling pathways,
including ER-associated protein degradation and unfolded
protein response (UPR).31,39,40 The UPR involves the activa-
tion of inositol-requiring protein1 (IRE1), PKR-like ER kinase
(PERK) and activating transcription factor 6 (ATF6), which
selectively suppress protein synthesis, promote the transla-
tion of specific proteins and regulate a wide variety of UPR
target genes expression, including several ER resident
chaperones as glucose-regulated protein 78 kDa (GRP78)
and protein disulfide isomerase (PDI) or pro-apoptotic
inducers as CHOP (also called GADD153).31,39,40
CHOP is the major pro-apoptotic transcription factor
induced by ER stress.39–42 Activating transcription factor 4
(ATF4), CCAAT/enhancer-binding protein beta (C/EBPb) and
CHOP complexes induce the transcription of several target
genes that lead to ER stress resolution or apoptosis. One of
these genes is TRB3, a novel target of CHOP/ATF4 also
involved in CHOP-dependent cell death as a second
messenger during ER stress.43 Nevertheless, the primary
role of UPR is to facilitate the cells to adapt to stress, as
revealed by increased sensitivity of ATF4-deficient cells to
amino-acid depletion and oxidative stress.44 ATF4 activity is
critical for maintaining metabolic homeostasis and cell
survival under nutrient deprivation.45 Thus, ATF4 activates
genes that promote restoration of normal ER function and
survival, and its elevated expression is associated with
resistance to current therapeutic agents including DNA
interacting and damaging drugs and proteasome inhibitors.46
We report that inhibition of PC synthesis by interfering with
choline kinase activity triggers an exacerbated and persistent
ER stress response that promotes cell death in breast, non-
small-cell lung cancer (NSCLC) and colon-derived tumor cells.
We identify CHOP as a key mediator in the cytotoxic effect
induced by ChoKa inhibition. By contrast, non-tumorigenic cells
exhibit a transient and attenuated ER stress response that
contributes to survival due to overproduction of ATF4. Our
results support that ChoKa inhibition is a bonafide target for
developing highly specific novel antitumor cancer drugs.
Results
ChoKIs arrest cell cycle in non-tumorigenic cells but
induce apoptosis in tumor cells. ChoKa inhibition by
MN58b has been previously shown to selectively induce cell
death in oncogene-transformed NIH3T3 cells and in Jurkat
tumor cells, but is cytostatic in non-tumorigenic and primary
cells.22,23 RSM932A has similar potential antitumor effects in
several cell lines being more potent than MN58b in inhibiting
ChoKa activity and intracellular PCho levels (data not shown).
Different epithelial mammary cell lines, including the tumor-
derived cell lines T47D, MDA-MB231 and MCF7, and the
immortalized non-tumorigenic mammary cell line MCF10A,
were exposed to MN58b or RSM932A at 15 mM (around
5xIC50), for 24 or 48 h. Consistent with the previous published
data in primary cells, ChoKa inhibition slowed down MCF10A
cell growth suggesting the induction of cell cycle arrest, but
reduction in cellular viability was not observed (Figure 1a).
In contrast, cellular viability significantly decreased in all tumor
cell lines studied (Figure 1a). Cell cycle modulation by ChoKIs
was further evaluated by propidium iodide (PI) flow cytometry
analysis. ChoKIs induced G1 phase cell cycle arrest in
MCF10A cells but induced cell death in T47D (Figure 1b),
MDA-MB231 and MCF7 tumor cell lines (data not shown).
Furthermore, DAPI staining revealed small and bright
nuclei and ‘apoptotic bodies’ in T47D cells (Supplementary
Figure 1A), conversely, MCF10A nuclei structure was not
modified after treatment.
Normal derived colon mucosa cell line NCM460,47 the
colorectal cancer cell line SW620 and the lung tumor-derived
cell line H460 were also analyzed to verify that the differential
effects observed were not cell type specific. As in mammary
cell lines and consistent with previous data, colorectal and
lung cancer cells were triggered to apoptosis, whereas normal
colon cells were arrested at G0/G1 after ChoKa inhibition with
either RSM932A or MN58b (Figure 1c).
A marked reduction in cyclin D1, phosphorylated and total
retinoblastoma protein (RB) and E2F1a was observed in
tumor cells (Supplementary Figure 1B), suggesting a defec-
tive regulation in the G0/G1 to S phase checkpoint. In non-
tumorigenic cells, a significant reduction in cyclin D1 and
phosphorylated RB (pRB) was also observed; however,
E2F1a and RB levels were only slightly modified, indicating
that G0/G1 arrest was due to the RB–E2F1a complex
(Supplementary Figure 1B). Tumor cells showed pro-caspase
3 and PARP degradation after 24 and 48 h of treatment,
suggesting that these proteins are not the main trigger
mechanism for the apoptotic program (Supplementary
Figures 1B and C).
ChoKIs induce exaggerated and persistent production
of ER stress-related proteins in tumor cells, but promote
moderated ER stress response in non-tumorigenic
cells. ER stress response is triggered by different cytotoxic
agents or intracellular toxic insults.39 Increased expression of
ER stress-related genes was observed as early as 6 h after
ChoKIs treatment, remaining elevated until 48 h, in T47D,
MDA-MB231 and MCF7 tumor cell lines (Supplementary
Figures 2 and 3). These genes were also upregulated
between 9 and 48 h in non-tumorigenic MCF10A cells
(Supplementary Figure 2). However, CHOP and C/EBPb
expression levels were higher in tumor cells than in the non-
tumorogenic cells MCF10A (Supplementary Figures 2A and B),
whereas ATF4 and TRB3 overexpression was markedly
higher in MCF10A (Supplementary Figures 2C and D).
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To further evaluate the effects of ChoKa inhibition on the
ER stress signaling pathway, protein levels were analyzed.
CHOP protein levels were significantly increased in T47D
cells as early as 9 h compared with non-tumorogenic
cells (Figure 2a), with a maximum at 24 h, and remained
elevated after 48 h. Similar data were observed for C/EBPb
(Figure 2b), GRP78 (Figure 2c), IRE1a (Figure 2d) and
TRB3 (Figure 2f), and confirmed in MDA-MB231 tumor-
derived cell line (Figure 2g). In T47D tumor cells, CHOP and
C/EBPb were located in the nuclei of the majority of cells
(Figure 3a). Conversely, although little effect was observed
for all these proteins in the non-tumorigenic MCF10A
cells (Figure 2a), ATF4 protein levels were significantly
increased (Figure 2e), mainly in the nuclei (Figure 3b),
suggesting that this transcription factor can have an
important role as a pro-survival factor in non-tumorigenic
cells.
PDI immunostaining showed a striking dilation in the ER of
ChoKIs-treated cancer cells, a hallmark of the ER stress
response40 (Figure 3c). PDI and CHOP proteins overproduc-
tion showed a similar effect that those observed in breast
cancer cells (Supplementary Figure 4).
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Figure 1 Choline kinase a inhibitors induce cell death in tumor cells and cause cell cycle arrest in non-tumorigenic cells. (a) MTT proliferation assay was performed in
MCF10A non-tumorigenic cells, T47D, MCF7, MDA-MB231 breast cancer cell lines. Figures show data as mean±S.E.M. of five independent experiments
each one performed in quadruplicated. *Po0.05 versus control cells after addition of ChoKIs. (b) Graph bars show DNA content analysis by PI, and flow
cytometry data shown as mean±S.E.M. of three independent experiments each one performed by duplicated. *Po0.05 versus control cells. (c) Bars show DNA
content analysis by flow cytometry data shown as mean±S.E.M. of three independent experiments each one performed by duplicated. *Po0.05 versus
control cells
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CHOP overproduction induced by ChoKIs is attenuated
when ChoKa protein levels are silenced. ChoKa siRNA
assays were performed in order to confirm that the ER stress
response induced by ChoKIs is due to their specific
interaction with ChoKa. Although pharmacological inhibition
of ChoKa induced a drastic alteration of CHOP, C/EBPb and
TRB3 (Figure 2), the partial ChoKa silencing achieved under
these conditions failed to trigger ER stress in T47D
(Figure 4a) and MDA-MB231 cells (Figure 4b). When cells
were treated with RSM932A or MN58b for an additional 24 h
after transfection with ChoKa siRNA for 48 h, the lower the
levels of ChoKa, the more attenuated was the induction of
CHOP by ChoKIs (Figure 4c and Supplementary Figure 5A),
indicating that ER stress response induced by ChoKIs is
triggered only in the presence of ChoKa. To support this
view, in vitro binding experiments of ChoKa with its inhibitor
RSM932A showed that this interaction induces a conforma-
tional change that can be followed by its sensitivity to trypsin
digestion that could trigger ER stress responses and CHOP-
dependent apoptosis (Supplementary Figure 5B).
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Figure 2 Choline kinase-a inhibitors markedly increase CHOP, C/EBPb, GRP78, IRE1a and TRB3 protein levels in tumor cells and ATF4 protein production in non-
tumorogenic cells. Left panel shows representative western blots for CHOP (a), C/EBPb (b), GRP78 (c), IRE1a (d), ATF4 (e) and TRB3 (f) in T47D and MCF10A cell lines
after treatment with ChoKa inhibitors. Right panel represents protein levels shown as mean±S.E.M. of four independent experiments. *Po0.05 versus control cells.
(g) Shows representative immunoblots of three independent experiments for CHOP, C/EBPb and TRB3 in MDA-MB231 cell line
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Figure 3 (a) CHOP and C/EBPb show nuclear location in T47D and MCF10A tumor cells after treatment with ChoKIs. Figure shows representative images of CHOP and
C/EBPb staining of three independent experiments for each cell type. (b) ATF4 shows specific nuclear location in non-tumorogenic cells. Representative images, of three
independent experiments, of ATF4 immunostaining. (c) ChoKIs induce PDI accumulation in tumor cells. The figure shows representative images of three independent
experiments for each cell type, acquired with confocal microscopy for PDI immunostaining (green), after 18 and 24 h of ChoKIs. Nuclei were stained with DAPI in all cases
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CHOP mediates the cytotoxic effect of ChoKIs in breast
cancer cells. As treatment with ChoKIs induces high levels
of CHOP, we next assessed whether CHOP has a role in
the cytotoxic effect of these inhibitors. CHOP siRNA was
used to efficiently silence the protein in both MDA-MB231
and T47D cells (Figure 5a and Figure 5b, respectively).
Flow cytometry analysis showed that ChoKIs did not
promote cell death in CHOP silenced cells compared with
controls (Figure 5c). Therefore, the induction of CHOP by
ChoKIs has a main role in the cytotoxic effect on tumor
cells.
TRB3 has been described as a target gene of CHOP and as
mediator of ER stress-induced apoptosis in several cell
types.36,43 We next asked whether CHOP regulated the
overproduction of TRB3 induced by ChoKIs. TRB3 levels
were found unaltered independently of the CHOP levels
(Figure 5d), suggesting that TRB3 overproduction is not
regulated by CHOP after ChoKIs treatment. The contribution
of TRB3 to the cytotoxic effect caused by ChoKIs was also
evaluated. TRB3 interference did not significantly modify the
induction of cell death by either RSM932A or MN58b
(Figure 5e), and it is not directly involved in cell death induced
by ChoKIs.
ATF4 has a survival role in non-tumorigenic cells.
Although ChoKIs induced ATF4 mRNA overexpression in
tumor and non-tumorigenic cells, its protein level and nuclear
location were only increased in the non-tumorigenic cells.
We assessed whether this protein could participate in the
cytostatic effect of ChoKIs in MCF10A. To that end, cells
were transiently transfected with ATF4 siRNA and 24 h later
treated with ChoKIs for 24 h (Figure 6a). Treatment with any
of the ChoKIs increased cell death in ATF4 silenced cells
(Figures 6b and c). These results demonstrate a crucial role
of ATF4 in survival and protection of non-tumorogenic cells
treated with RSM932A or MN58b.
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Discussion
The relevance of ChoKa in tumor growth has been reported in
some types of cancer where this enzyme was found to be
overexpressed with high incidence.9,11 ChoKa-specific inhibi-
tors have been generated with proven antiproliferative activity
in vitro and in vivo.20–23 The antitumor action of ChoKIs relies
on the ability of these compounds to directly affect cellular
viability through induction of apoptosis. In contrast, in non-
tumorigenic cells the blockage of de novo PCho synthesis by
MN58b results in a reversible cell cycle arrest at G0/G1
phase.25 Here, we further confirm that MN58b and RSM932A
exert cytotoxic effect in a variety of tumor cells and a cytostatic
effect inducing G1 cell cycle arrest in non-tumorigenic
mammary cells and normal derived colon mucosa primary
cells. ChoKIs induced a marked deficiency in G1 to S phases
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checkpoint mediators (cyclin D1, RB and E2F1a) in tumor
cells, but in non-tumorigenic cells, the levels of E2F1a and
total RB are scarcely altered suggesting that arrest in G0/G1
may be due to maintenance of the RB-E2F1a complex. Our
data clearly indicate that RSM932A and MN58b have a
differential cytostatic effect on non-tumorigenic cells and a
cytotoxic effect on tumor cells, supporting further the use of
ChoKIs as a novel and potent antitumor strategy with specific
antiproliferative activity against different types of human
tumor cells.
In human cancer cell lines, ChoKa inhibition promotes an
exacerbated ER stress response, sustained by GRP78,
C/EBPb, IRE1a and TRB3 production, which leads to CHOP-
dependent apoptosis. Cell death mechanisms triggered by
ER stress include both caspase-dependent apoptosis and
caspase-independent necrosis.48 Moreover, only tumor cells
showed pro-caspase 3 and PARP degradation, suggesting
that these proteins are being ripped off as a consequence of
ER stress activation of ChoKIs. Whether ChoKIs induce ER
stress apoptosis mediated by necrosis should be further
investigated.
The ER is an organelle that has essential roles in multiple
cellular processes required for cell survival and normal cellular
functions. Recent studies suggest an important role of ER
stress in carcinogenesis, and alterations in ER homeostasis
have been correlated with pathological states and particularly
with cancer. Interfering with the activation of different arms of
the UPR can inhibit tumor growth in vivo, arguing that it
contributes to survival or growth of some cancer cells.49 The
UPR is primarily an adaptive response to support cell survival
by a selective induction of transcription, but if homeostasis
cannot be re-established, the UPR triggers cell death.
According to this, some antitumor agents, including vorino-
stat, sorafenib, tocotrienol, delta(9)-tetrahydrocannabinol,
fenretinide and bortezomib lead to apoptosis induced by ER
stress.33–36,38 The ability of the cells to handle this stress, and
transcriptional and translational regulation of ER stress
mediators, may therefore condition their intrinsic capacity to
adapt for cell survival or, alternatively, to start the apoptotic
program through ER-associated machineries. In this sense,
ChoKIs activate ER stress maintained response in tumor
cells, but a slight ER proteins production was observed in non-
tumor cells, indicating a different ability in both tumor and non-
tumor cells to re-establish ER homeostasis disturbed by
ChoKIs.
The results obtained after ChoKIs treatment of non-
tumorigenic cells indicate that these cells are prone to ER
stress adaptation through ATF4 overproduction and mode-
rated increase of CHOP and C/EBPb. In fact, ATF4 nuclear
location was only observed in non-tumorigenic cells, suggesting
that only in these cells it is activating its target genes.
In keeping with this, inhibition of ATF4 expression blocked
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proliferation and survival of non-tumorigenic cells. Moreover,
HEK293 cells overexpressing ATF4 showed retarded growth
in complete medium.50 We have observed increased cell
death in non-tumorigenic cells silenced for ATF4 after
treatment with ChoKIs, supporting its protective and pro-
survival role.
Recent studies suggest that when a stress transcends from
acute to persistent, the regulatorymechanisms based onUPR
would promote sustained elevated levels of CHOP protein
(despite of its short half-life), and the products of its target
genes, triggering apoptotic pathways.51 CHOP is ubiquitously
expressed at very low levels, and markedly expressed by
perturbations that induce stress in a wide variety of cells.41,52
Upon non-stressed conditions, CHOP remains in the cytosol,
and stress leads to its accumulation in the nucleus.41 The
overinduction of ER stress response observed after ChoKIs
treatment is not cell type specific as ChoKIs trigger this
process in several types of breast, colon and lung cancer
cells. CHOP protein levels were significantly increased at all
times studied and accompanied by a significant increase of
C/EBPb, GRP78, IRE1a, TRB3 and PDI, well-known markers
for ER stress. In addition, ChoKIs also recruit CHOP and
C/EBPb in the nuclei at the same time, promoting its
dependent transcriptional program in tumor cells. We show
a sustained significant increase of CHOP, mainly located in
the nuclei. In addition, CHOP blockage using specific siRNA,
abolished apoptosis induced by ChoKIs in tumor cells. CHOP
silencing also induced a reduction on C/EBPb, ATF3 and
GRP78 protein levels (data not shown), which in addition are
also direct inducers of CHOP. Cells lacking C/EBPb (major
partner of CHOP) are also resistant to ER stress-induced
apoptosis.42 Thus, a specific, potent, overstated and persis-
tent induction of ER proteins by ChoKIs drives the tumor cells
to apoptosis mediated by elevated levels of CHOP.
TRB3 has been described as a novel ER stress-inducible
gene that is a direct transcriptional target of ATF4 and CHOP
and may have an important role in ATF4/CHOP-mediated
apoptosis.43 Knockdown of ATF4 or CHOP significantly
suppressed the induction of TRB3 in HEK293.50 Conversely,
no change was observed in TRB3 levels in CHOP silenced
cells treated with RSM932A or MN58b, indicating that in this
case TRB3 is not directly involved in the cytotoxic effect of
high levels of CHOP. The implication of TRB3 in themechanism
of action of ChoKIs has to be more deeply investigated.
PC depletion can disturb the ER function and result in ER
stress.32,53 Inhibition of PC synthesis through mutated
CTP:phosphocholine cytidylyltransferase enzyme leads spe-
cifically to induction of the ER stress-related protein CHOP
and apoptosis.32 Moreover, the C/EBP-ATF composite sites
are required for the increased expression of CHOP during PC
depletion and might be mediated by binding of ATF2 to this
element.53 The specific effect of ChoKIs is not observed after
siRNA ChoKa inhibition. Specific pharmacological inhibition
and ChoKa siRNA efficiently reduced ChoKa activity and
PCho levels,15–18 but ChoKa siRNA failed in the activation of
ER stress response. The different strategies to block ChoKa
by siRNA or specific pharmacological inhibition might explain
this differential effect. Our results indicate that ER stress
response triggered by ChoKIs depends on the presence
of ChoKa, as the higher the silencing of ChoKa protein,
the lesser the induction of CHOP was observed after ChoKIs
treatment. In vitro binding experiments suggest that ChoKa
conformation might be modified after ChoKIs interaction,
increasing the potential of apoptosis induction of this family of
inhibitors by combining a metabolic effect by depleting PC
synthesis, and a UPR response. These results are consistent
with a dual effect of ChoKIs and are in keeping with recent
reports demonstrating a complex interaction of ChoKa with its
inhibitors.54,55
Accumulation of proteins with wrong conformations or
unfolded proteins in the ER results in the induction of several
proteins, including the ER chaperones GRP78 and GRP94,
which facilitates proper protein folding by interacting with
exposed hydrophobic patches on protein-folding intermedi-
ates and is thought to prevent their aggregation while
maintaining the protein in a folding-competent state.32,56
Furthermore, ER stress can activate transmembrane proteins
located in the ER membrane like IRE1a and PERK, which
inhibit general protein synthesis and activate the non-
canonical apoptosis response. ChoKIs dramatically increase
GRP78, IRE1a and CHOP, which suggests that the exacer-
bated induction of ER stress response depends on ChoKa
protein presence in the cells, and the levels of ChoKa are
crucial for the ER stress-mediated apoptosis by these
inhibitors. Furthermore, non-cytotoxic doses of both MN58b
and RSM932A showed a significant increase of CHOP in a
dose-dependent manner (data not shown), which dismisses
that it is an off-target effect and support that ER stress
induction caused by ChoKIs may be directly related to the
inhibition of ChoKa activity.
In summary, ChoKa inhibition leads to exacerbated ER
stress response and CHOP overproduction that has a crucial
role in the cytotoxic effect of ChoKIs in tumor cells. In addition,
ATF4 might represent a pathway for cell survival in non-
tumorigenic cells. Our data provide relevant evidence for a
rational understanding of the selective and specific apoptotic
effect on tumor cells, and support further preclinical and
clinical studies with this novel family of anticancer drugs.
Materials and Methods
Cell culture and reagents. Cell lines were grown under standard
conditions: T47D (epithelial mammary cells from ductal carcinoma), MCF7
(epithelial mammary gland cells from adenocarcinoma), H460 (epithelial large cell
non-small-cell lung cancer); were cultured in RPMI (Invitrogen, Casbard, CA,
USA); MDA-MB231 (epithelial mammary gland cells from adenocarcinoma) and
SW620 (colorectal adenocarcinoma), cultured in DMEM (Invitrogen), supplemented
all of them with 10% fetal bovine serum (Invitrogen). MCF10A (non-tumorigenic
epithelial gland mammary cell line) were grown in DMEM-F12 (Invitrogen)
supplemented with 10% newborn calf serum (Biochrom, Berlin, Germany),
10mg/ml Epidermal growth factor (Calbiochem, Merck, Darmstadt, Germany),
50 mg/ml hydrocortisone, 2.5 mg/ml insulin and 100 ng/ml cholera toxin
(from Sigma-Aldrich, St. Louis, MO, USA). NCM460 cells (normal derived colon
mucosa cells) were received by a licensing agreement with INCELL Corporation
(San Antonio, TX, USA). They were routinely propagated on M3BASE medium plus
supplements and 10% FBS. All experiments were performed at 50% of confluence.
First- and second-generation inhibitors of ChoKa were used. MN58b was
dissolved in water at 5 mmol, and RSM932A was dissolved in DMSO : Water (2 : 1)
at 5 mmol. The vehicle DMSO : Water (2 : 1) were used as Control. Both drugs are
produced at Prof. Lacal’s laboratory and are not available as commercial
compounds.
Flow cytometry analysis. Cells were seeded at a density of 20 104 cells/
well on six-well plates and treated 24 h later with MN58b and RSM932A.
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Supernatants and cultured cells were collected and centrifuged at 1800 r.p.m. for
15 min. Then cells were diluted in 1 PBS with PI (50mg/ml), RNAse A (20mg/ml)
and TX-100 (50 ml). The DNA content of stained cells was analyzed using a
FACScan flow cytometer (Becton Dickinson and Company, Franklin Lakes, NJ,
USA) and Cell Quest Pro software (Becton Dickinson and Company). The fraction
of cells in apoptosis (sub-G1), G0-G1, S and G2-M phases were quantified by
MODFIT LT 3.0 software (Verity Software House, Topsham, ME, USA).
Cell viability assays (MTT). Cells were seeded at a density of 5 103
cells/well on 96-well plates. Then, cells were treated with MN58b or RSM932A
during 24 and 48 h. Cellular viability was studied by 3-(4,5-dimethylthiazol-2yl)-2,
5-diphenyl tetrazoliumbromide (MTT) method (Invitrogen). Absorbance was read at
560 nm in a VersaMax Microplate Reader (Molecular Devices, Sunnyvale, CA, USA).
Protein analysis. Equal amounts of lysed proteins were separated by
SDS-PAGE electrophoresis, transferred onto nitrocellulose membranes using iBlot Dry
Blotting System (Invitrogen) and immunoblotted with pro-caspase 3; cyclin D1,
phospho-RB, RB (Santa Cruz Biotechnology, Heidelberg, Germany); CHOP, GRP78
and IRE1a (Cell Signaling, Danvers, MA, USA); C/EBPb, TRB3, ATF4, ATF3
(AbCam, Cambridge, UK) and ChoKa antibody. a-Actin (Sigma-Aldrich) and GAPDH
(Millipore, Billerica, MA, USA) were used as loading controls. Membranes were
incubated with peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology)
and developed using an ECL chemiluminiscence kit (Amersham Pharmacia Biotech,
Piscataway, NJ, USA). Autoradiographs were scanned and Quantity One software
was used for densitometric analyses (Bio-Rad, Madrid, Spain).
Gene expression studies. Total mRNA was isolated using RNeasy mini Kit
(Qiagen, Hilden, Germany). cDNA was synthesized using High Capacity cDNA
Archive Kit (Applied Biosystems, Life Technologies, Carlsbad, CA, USA) using
1mg of total RNA primed with random hexamer primers following the
manufacturer’s instructions. Real-time RT-PCR was performed using fluoro-
genic TaqMan gene expression assays (Applied Biosystems): CHOP
(Hs_01090850_m1), C/EBPb (Hs_00270923_s1), ATF4 (Hs_00909569_g1) and
TRB3 (Hs_00221754_m1). Data were normalized with 18S eukaryotic ribosomal
RNA expression (Hs99999901_m1). The mRNA copy numbers were calculated for
each sample by the instrument software using Ct value (‘arithmetic fit point
analysis for the lightcycler’). Results are expressed as the quantity of the target
gene after treatment relative to unstimulated cells, after normalization against 18S.
siRNA and shRNA transfection studies. Cells were transfected using
Lipofectamine 2000 reagent (Invitrogen) and 30 nM siRNA for ATF4 (Eurogentec
S.A., Liege, Belgium), CHOP on-target plus SMARTpool CHOP (Dharmacon Inc.,
Chicago, IL, USA), ChoKa (Qiagen) and non-targeted siRNA as control (Ambion,
Life Technologies, Carlsbad, CA, USA) as described by the manufacturer’s
instructions. Lentiviruses were generated by co-transfecting Hek293T cells with
10mg of TRB3 shRNA-encoding plasmid (Dharmacon Inc.) and 8.75mg each of
pDelta 8.9 (ps_PAX29 and VSV-60 (pMD2.G) plasmids using Lipofectamine 2000
(Invitrogen). Growth media were exchanged the following day and lentivirus-
containing supernatant was harvested 48 h later. Target cell lines were transduced
with lentiviral RNAi at MOI¼ 1 and selected in 1 mg/ml puromycin for 1 week.
Native gel analysis. Ten micromolar samples of Plasmodium falciparum and
human choline kinase were incubated with DMSO or 100mM of RSM932A in
Kinase Buffer (100 mM Tris, pH 8, 10 mM MgCl2) for 1.5 h on ice and after the
addition of an appropriate loading buffer were loaded onto a 4–20% Mini-Protean
TGX native gel (Bio-Rad).
Trypsin degradation. Ten micromolar samples of P. falciparum and human
choline kinase were incubated with either DMSO or 100mM of RSM932A in
Kinase Buffer in the presence of 3 mg/ml of trypsin at 37 degrees for 1 h. Samples
aliquots were removed at 5, 10, 20, 30 and 60 min, and placed on ice. Sample
buffer was immediately added and trypsin degradation reaction was stopped by
incubating for 5 min at 95 degrees. Samples were then loaded onto a 12%
SDS-PAGE gel. Coomasie-stained bands representing undegraded choline kinase
were quantified using the Quantity One software and normalized against a band
representing a sample lacking trypsin.
Immunofluorescence staining. To assess CHOP, C/EBPb, ATF4 and
PDI staining, cells were fixed with 4% PFA. After permeabilizing with 0.3%
TX-100, samples were blocked with 4% BSA and incubated with primary
antibodies: PDI, CHOP (Cell Signaling), C/EBPb and ATF4 (Santa Cruz
Biotechnology). After washing, cells were incubated with Alexa secondary
antibodies (Invitrogen), and nuclei were stained with DAPI (Invitrogen). Negative
control was performed in the absence of primary antibody or using non-related
secondary antibodies. Samples were mounted with ProLong gold (Invitrogen) and
examined using TSC SP2 confocal microscope (Leica, Barcelona, Spain).
Statistical analysis. One-way ANOVA was used to compare gene and/or
protein expression levels between groups. When statistical significance was found,
the Bonferroni post hoc comparison test was used to identify differences between
groups. Differences were considered significant at Po0.05. Statistical analyses
were performed using the SPSS statistical software, version 11.0.
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